Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, schizophrenia, diabetes, ADHD and chronic migraine.

Latest News

Sep 16, 2014

Heptares To Present On Structure-based Drug Design Using G Protein-coupled Reception At Inaugural Chemistry & Engineering News Virtual...

Jul 7, 2014

Heptares Announces Publication In Nature Of First Structure Of Metabotropic Glutamate Receptor 5 Transmembrane Domain


Sep 21-24, 2014
Fragment-based Lead Discovery
Basel, Switzerland
Presenting: Rob Cooke

Sep 22-24, 2014
BioPharm America
Boston, MA, USA
Attending: Dan Grau

© 2012-2014 Heptares Therapeutics